Molecular Partners AG, a clinical-stage biotech company, has announced a strategic partnership with Orano Med, a clinical-stage radiopharmaceutical company. This collaboration aims to develop a new class of targeted alpha-particle therapies using Molecular Partners' proprietary DARPin therapeutics platform. The joint effort has led to the nomination of MP0726, a Radio-DARPin candidate targeting mesothelin, for the treatment of ovarian cancer. Demonstrating promising preclinical results, this partnership combines Molecular Partners' expertise in custom-built protein drugs with Orano Med's advanced radiopharmaceutical capabilities, positioning them to address important unmet medical needs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。